The law firm of Kirby McInerney LLP is investigating potential claims against Trevena Inc. (Trevena or the Company) (NASDAQ:TRVN). This investigation concerns whether Trevena has violated federal securities laws and/or engaged in other unlawful business practices.
On May 2, 2016, Trevena announced that it had reached general agreement with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was very pleased with the outcome of its discussions with the FDA.
However, on October 9, 2018, minutes from the FDA’s April 28, 2016 meeting with Trevena were released and showed that the FDA: did not agree with the proposed dosing in the Phase 3 studies; did not agree with the proposed primary endpoint; and did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine.
On this news, Trevena shares fell $1.91, or over 64%, to close at $1.07 on October 9, 2018.
If you purchased or otherwise acquired Trevena securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, and whistleblower litigation. The firms efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLPs website: www.kmllp.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.